全文获取类型
收费全文 | 1018篇 |
免费 | 70篇 |
国内免费 | 64篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 60篇 |
妇产科学 | 4篇 |
基础医学 | 99篇 |
口腔科学 | 36篇 |
临床医学 | 85篇 |
内科学 | 217篇 |
皮肤病学 | 28篇 |
神经病学 | 30篇 |
特种医学 | 261篇 |
外科学 | 73篇 |
综合类 | 64篇 |
预防医学 | 32篇 |
眼科学 | 6篇 |
药学 | 127篇 |
中国医学 | 3篇 |
肿瘤学 | 25篇 |
出版年
2023年 | 5篇 |
2022年 | 5篇 |
2021年 | 21篇 |
2020年 | 9篇 |
2019年 | 12篇 |
2018年 | 18篇 |
2017年 | 9篇 |
2016年 | 13篇 |
2015年 | 18篇 |
2014年 | 28篇 |
2013年 | 36篇 |
2012年 | 17篇 |
2011年 | 24篇 |
2010年 | 28篇 |
2009年 | 35篇 |
2008年 | 16篇 |
2007年 | 48篇 |
2006年 | 21篇 |
2005年 | 32篇 |
2004年 | 13篇 |
2003年 | 14篇 |
2002年 | 13篇 |
2001年 | 27篇 |
2000年 | 14篇 |
1999年 | 25篇 |
1998年 | 57篇 |
1997年 | 63篇 |
1996年 | 57篇 |
1995年 | 57篇 |
1994年 | 34篇 |
1993年 | 42篇 |
1992年 | 16篇 |
1991年 | 19篇 |
1990年 | 22篇 |
1989年 | 49篇 |
1988年 | 36篇 |
1987年 | 35篇 |
1986年 | 19篇 |
1985年 | 22篇 |
1984年 | 12篇 |
1983年 | 7篇 |
1982年 | 15篇 |
1981年 | 18篇 |
1980年 | 19篇 |
1979年 | 13篇 |
1978年 | 5篇 |
1977年 | 14篇 |
1976年 | 10篇 |
1975年 | 7篇 |
1970年 | 1篇 |
排序方式: 共有1152条查询结果,搜索用时 24 毫秒
101.
Weisdorf DJ; Verfaillie CM; Davies SM; Filipovich AH; Wagner JE Jr; Miller JS; Burroughs J; Ramsay NK; Kersey JH; McGlave PB 《Blood》1995,85(12):3452-3456
Delay in hematologic recovery after bone marrow transplantation (BMT) can extend and amplify the risks of infection and hemorrhage, compromise patients' survival, and increase the duration and cost of hospitalization. Because current studies suggest that granulocyte- macrophage (GM) colony-stimulating factor (CSF) may potentiate the sensitivity of hematopoietic progenitor cells to G-CSF, we performed a prospective, randomized trial comparing GM-CSF (250 micrograms/m2/d x 14 days) versus sequential GM-CSF x 7 days followed by G-CSF (5 micrograms/kg/d x 7 days) as treatment for primary or secondary graft failure after BMT. Eligibility criteria included failure to achieve a white blood cell (WBC) count > or = 100/microL by day +21 or > or = 300/microL by day +28, no absolute neutrophil count (ANC) > or = 200/microL by day +28, or secondary sustained neutropenia after initial engraftment. Forty-seven patients were enrolled: 23 received GM-CSF (10 unrelated, 8 related allogeneic, and 5 autologous), and 24 received GM- CSF followed by G-CSF (12 unrelated, 7 related allogeneic, and 5 autologous). For patients receiving GM-CSF alone, neutrophil recovery (ANC > or = 500/microL) occurred between 2 and 61 days (median, 8 days) after therapy, while those receiving GM-CSF+G-CSF recovered at a similar rate of 1 to 36 days (median, 6 days; P = .39). Recovery to red blood cell (RBC) transfusion independence was slow, occurring 6 to 250 days (median, 35 days) after enrollment with no significant difference between the two treatment groups (GM-CSF: median, 30 days; GM-CSF+G- CSF; median, 42 days; P = .24). Similarly, platelet transfusion independence was delayed until 4 to 249 days (median, 32 days) after enrollment, with no difference between the two treatment groups (GM- CSF: median, 28 days; GM-CSF+G-CSF: median, 42 days; P = .38). Recovery times were not different between patients with unrelated donors and those with related donors or autologous transplant recipients. Survival at 100 days after enrollment was superior after treatment with GM-CSF alone. Only 1 of 23 patients treated with GM-CSF died versus 7 of 24 treated with GM-CSF+G-CSF who died 16 to 84 days (median, 38 days) after enrollment, yielding Kaplan-Meier 100-day survival estimates of 96% +/- 8% for GM-CSF versus 71% +/- 18% for GM-CSF+G-CSF (P = .026). These data suggest that sequential growth factor therapy with GM-CSF followed by G-CSF offers no advantage over GM-CSF alone in accelerating trilineage hematopoiesis or preventing lethal complications in patients with poor graft function after BMT.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
102.
A two-color flow cytometry assay for detection of hairy cells using monoclonal antibodies 总被引:2,自引:0,他引:2
We have developed a simple two-color immunofluorescence assay equally suited for microscopy and flow cytometry detecting hairy cells (HCs) in single cell suspensions, based on the concomitant reactivities with the B cell-specific monoclonal antibody B1 (CD20) and the monocyte/HC- associated antibody SHCL-3 (CD11c). Thus, HCs can be demonstrated in peripheral blood, bone marrow, and spleen specimens from hairy cell leukemia (HCL) patients even when they constitute less than 1% of the cell suspension. Likewise, admixture experiments with normal mononuclear cells and the MOLT-4 T-acute lymphocytic leukemia (ALL) cell line demonstrated that HCs could be detected in amounts as low as 1%. The validity of this assay has been ascertained by the lack of double marker positivity in cell suspensions from B-chronic lymphocytic leukemia (CLL) and acute myelogenous leukemia (AML) patients that only expressed B1 or SHCL-3, respectively. Furthermore, other malignant blood diseases, including malignant lymphomas, acute leukemias, and chronic leukemias disclosed no double marker positive cells. In a clinical setting, this assay was used for purifying HCs (by flow cytometry) from the peripheral blood from patients with no apparent morphological evidence of circulating HC infiltration and for monitoring the effect of interferon therapy. In conclusion, this assay should be of value for both diagnosis and monitoring patients with HCL. 相似文献
103.
J.J. Dalal R.R. Kasliwal A.L. Dutta J.P.S. Sawhney S.S. Iyengar S. Dani N. Desai I. Sathyamurthy D. Rao A. Menon A. Dasbiswas G.S. Wander M. Chadha M.S. Hiremath D.G. Roy V. Gupta N. Shivakadaksham 《Indian heart journal》2012,64(5):503-507
IntroductionSudden cardiac death (SCD) is the most lethal manifestation of heart disease. In an Indian study the SCDs contribute about 10% of the total mortality and SCD post ST elevation myocardial infarction (MI) constitutes for about half of total deaths.ObjectiveGiven the limitations of existing therapy there is a need for an effective, easy to use, broadly applicable and affordable intervention to prevent SCD post MI. Leading cardiologists from all over India came together to discuss the potential role of n-3 acid ethyl esters (90%) of eicosapentaenoic acid (EPA) 460 mg & docosahexaenoic acid (DHA) 380 mg in the management of post MI patients and those with hypertriglyceridemia.RecommendationsHighly purified & concentrated omega-3 ethyl esters (90%) of EPA (460 mg) & DHA (380 mg) has clinically proven benefits in improving post MI outcomes (significant 15% risk reduction for all-cause mortality, 20% risk reduction for CVD and 45% risk reduction in SCD in GISSI-Prevenzione trial) and in reducing hypertriglyceridemia, and hence, represent an interesting option adding to the treatment armamentarium in the secondary prevention after MI based on its anti-arrhythmogenic effects and also in reducing hypertriglyceridemia. 相似文献
104.
The epidemiology of hyperuricaemia and gout in Taiwan aborigines 总被引:4,自引:1,他引:4
To determine the prevalence of hyperuricaemia, gout and gout-related
factors in Central Taiwan Atayal aborigines, 342 subjects over 18 yr old
were interviewed and examined. A questionnaire was designed to screen for
signs and symptoms of gout and gout-related risk factors. Serum uric acid,
triglyceride and creatinine were measured in all subjects. The prevalence
of hyperuricaemia was 41.4% and that of gout 11.7% in aborigines. The uric
acid level was 7.9+/-1.7 mg/dl in males and 5.7+/-1.5 in females, and
differed significantly under age 70 yr (P < 0.001). Significantly
increased triglyceride, creatinine and alcoholism was found in gouty
patients compared with non-gouty patients. In 40 cases with gout, 54% had
tophi and 35% of their first- degree relatives had gout. The high
prevalence of hyperuricaemia and gout in Taiwan Atayal aborigines, a
significant family predisposition, increased creatinine level and
alcoholism suggest multiple factors affecting the hyperuricaemia.
相似文献
105.
Functional abnormalities of CD8+ T cells define a unique subset of patients with common variable immunodeficiency 总被引:3,自引:1,他引:3
A substantial subgroup of patients with common variable immunodeficiency (CVI) exhibit an abnormal T-cell phenotype characterized by a low CD4/CD8 ratio associated with a significant increase in the absolute number of CD8+ T cells (CVI4/8low patients). In the present study, we examined the phenotypic and functional properties of purified T-cell subsets in this group of CVI patients. CD8+ T cells from CVI4/8low patients manifested increased expression of HLA-DR and CD57 and decreased expression of CD45RA as compared with CD8+ T cells from normal controls. When stimulated with anti-CD3 and phorbol 12-myristate 13-acetate, purified patient CD8+ T cells exhibited significantly decreased proliferation, c-myc expression, and interleukin-2 (IL-2) production compared with that of normal CD8+ T cells. Nevertheless, mitogen-activated patient CD8+ T cells secreted elevated amounts of gamma-interferon and IL-5 and normal amounts of IL- 4. This abnormal pattern of proliferation and cytokine production was limited to the CD8+ T-cell subset as CD4+ T cells from these patients exhibited normal proliferation and cytokine production. In further functional studies, purified CD8+ T cells from CVI4/8low patients manifested increased cytotoxic T-lymphocyte activity and suppressor activity, as compared with normal CD8+ T cells, when they were tested in (1) an anti-CD3 "redirected" cytotoxicity assay and (2) a suppressor assay consisting of CD8+ T cells and Staphylococcus aureus Cowan I (SAC) plus IL-2-stimulated normal (allogeneic) B cells. In the latter case, patient CD8+ T cells suppressed IgG production, but not IgM production. Finally, in studies to evaluate the role of patient CD8+ T cells in the pathogenesis of hypogammaglobulinemia, we determined the capacity of SAC and IL-2 to induce Ig production in highly purified patient B cells, ie, in the absence of patient CD8+ T cells. We found that, whereas B cells from one patient produced normal amounts of IgG, B cells from three patients were unable to produce normal amounts of IgG under these conditions. These data establish the phenotypic and functional characteristics of CD8+ T cells in CVI4/8low and clearly distinguish CVI4/8low patients from other patients with this syndrome. The data do not support the contention that hypogammaglobulinemia in CVI4/8low patients is due to a direct effect of CD8+ T cells on terminal B-cell differentiation, except in the occasional patient. The abnormal CD8+ T cells may, nevertheless, have more subtle effects of lymphoid function that play a role in disease pathogenesis. 相似文献
106.
107.
108.
109.
锌酞菁脂质体光动力作用引起小鼠肿瘤的细胞程序性死亡 总被引:4,自引:1,他引:3
电镜观察了锌酞菁脂质体光动力作用引起小鼠MS-2纤维肉瘤的形态学变化。发现其作用很强,并对肿瘤细胞有明显的直接影响。肿瘤细胞的结构表现出明显的程序性细胞死亡(apoptosis,programmedceldeath)的特点:胞核染色质凝聚边集、核固缩、核破裂、染色质凝块流失、胞质内吞噬现象、胞膜表面肿胀粗钝的胞突形成、细胞碎裂等。加深了对锌酞菁脂质体光敏作用机理的认识,但其详细的发生机制和调节途径有待阐明。 相似文献
110.
Patients infected with influenza A virus (IAV) are at increased risk for bacterial superinfections, and this occurs in association with depressed polymorphonuclear leukocyte (PMNL) function. Recently, we reported that in vitro exposure of human PMNL to granulocyte-macrophage colony-stimulating factor (GM-CSF) reverses IAV-induced cell dysfunction. The present study used an established animal model of IAV infection to examine whether G-CSF and/or GM-CSF can overcome IAV- induced PMNL dysfunction and thereby prevent secondary infections. Preliminary studies determined a dosing schedule of these cytokines that caused significant priming of chinchilla PMNL. In subsequent studies, animals were inoculated intranasally with IAV (day 1) followed 3 days later by Streptococcus pneumoniae, and administered daily intraperitoneal injections with a cytokine or placebo on days 3 through 9. Animals had blood obtained on multiple occasions for PMNL studies, and were followed-up for evidence of pneumococcal disease. Both cytokines caused significant priming of the PMNL chemiluminescence response and this was associated with reversal of the IAV-induced PMNL dysfunction. However, neither cytokine decreased the incidence of pneumococcal disease. 相似文献